Patents Examined by Sally Teng
-
Patent number: 6140073Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.Type: GrantFiled: January 16, 1996Date of Patent: October 31, 2000Assignee: Merck & Co., Inc.Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
-
Patent number: 6087144Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: GrantFiled: May 22, 1995Date of Patent: July 11, 2000Assignee: Genentech, Inc.Inventors: David T. Scadden, Kevin P. Baker, Will F. Baron
-
Patent number: 6071715Abstract: The retinoblastoma protein (Rb) is the product of the retinoblastoma gene and has been found to contain mutations in retinoblastoma tumor cells. Two nuclear proteins that bind to Rb, p48 and p46 have been isolated and the genes have been cloned. These proteins bind to Rb competitively with the SV40 T antigen. p48 is shown to suppress heat shock sensitive Ras mutations in yeast and is implicated as a modulator of the retinoblastoma suppressor function of Rb.Type: GrantFiled: August 12, 1993Date of Patent: June 6, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Yue-Wei Qian, Eva Y. H. P. Lee
-
Patent number: 6048711Abstract: A novel G-protein coupled receptor protein, a partial peptide and their salts are disclosed. DNA encoding the receptor protein, production of the receptor protein, determination of a ligand to the receptor protein, a method for screening for compounds which inhibit ligand binding to the receptor protein, a kit for screening for such compounds are also disclosed. The receptor protein, its partial peptide and their salts are used for screening for candidate compounds of drugs and the like.Type: GrantFiled: October 28, 1997Date of Patent: April 11, 2000Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Shoji Fukusumi, Yuji Kawamata
-
Patent number: 6031079Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.Type: GrantFiled: February 23, 1999Date of Patent: February 29, 2000Assignees: Merck Frosst Canada, Inc., Vanderbilt UniversityInventors: Anthony Ford-Hutchinson, Richard Grygorczyk, Collin Funk, Kathleen Metters
-
Patent number: 6028175Abstract: The present invention relates to a novel mammalian methadone-specific opioid receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue of the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: October 13, 1998Date of Patent: February 22, 2000Assignee: Oregon Health Science UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 6027927Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobin sequences.Type: GrantFiled: October 1, 1997Date of Patent: February 22, 2000Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 5998187Abstract: Novel receptor tyrosine kinase protein and isoforms thereof which are expressed in cells of the endothelial lineage, and DNA segments encoding the novel protein and isoforms thereof are disclosed. Methods for identifying ligands which are capable of binding to the receptor protein and methods for screening for agonist or antagonist substances of the interaction of the protein and a ligand are also disclosed.Type: GrantFiled: April 23, 1997Date of Patent: December 7, 1999Assignee: Mount Sinai Hospital CorporationInventors: Martin L. Breitman, Janet Rossant, Daniel J. Dumont, Terry P. Yamaguchi, Jo-Ann Breitman
-
Patent number: 5998172Abstract: The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.Type: GrantFiled: July 18, 1996Date of Patent: December 7, 1999Assignees: Duke University, Bristol-Myers Squibb CompanyInventors: Barton F. Haynes, Alejandro Aruffo, Dhavalkumar D. Patel, Michael A. Bowen, Hans Marquardt, Anthony W. Siadak
-
Patent number: 5989833Abstract: Polypeptide of a growth factor receptor family, having a specific sequence and presenting all or part of the following properties: it encourages and/or is involved in the proliferation and/or differentiation of hematopoietic cell lines when obtained from the MPLV retrovirus; it is capable of acting as a hematopoietic growth factor receptor; it is recognized by antibodies directed against it. Polypeptides similar to the above. Applications in the diagnosis of the expression of said ligand polypeptide.Type: GrantFiled: June 2, 1995Date of Patent: November 23, 1999Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Martine Charon, Sylvie Gisselbrecht, Jean-Francios Penciolelli, Michele Souyri, Pierre Tambourin, Paule Varlet, Isabelle Vigon, Francoise Wendling
-
Patent number: 5986081Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome rare, but often fatal, cardiac arrhythmia.Type: GrantFiled: October 22, 1997Date of Patent: November 16, 1999Assignee: Wisconsin Alumni Research FoundationInventors: Barry S. Ganetzky, Steven A. Titus
-
Patent number: 5976834Abstract: HNFJD15 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFJD15 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: January 9, 1997Date of Patent: November 2, 1999Assignee: SmithKline Beecham CorporationInventors: Ganesh Madhusudan Sathe, Wendy S. Fuetterer, Derk John Bergsma, Catherine Ellis
-
Patent number: 5900400Abstract: Analogs of the serine protease inhibitors in which the amino acid sequence is varied slightly are disclosed, which analogs variously show improved properties including improved resistance to oxidative inactivation, improved ability to inhibit pancreatic elastase, improved ability to inhibit cathepsin G, and improved ability to inhibit trypsin.Type: GrantFiled: July 29, 1994Date of Patent: May 4, 1999Assignee: Amgen Inc.Inventors: Robert C. Thompson, Kjell Ohlsson
-
Patent number: 5863755Abstract: A novel receptor-type protein tyrosine phosphatase-.kappa. (RPTP.kappa.) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP.kappa. protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP.kappa. molecules are provided.Type: GrantFiled: July 1, 1993Date of Patent: January 26, 1999Assignees: Max Planck Gessellschaft, New York University Medical CenterInventors: Joseph Schlessinger, Jan M. Sap, Axel Ullrich, Wolfgang Vogel, Miriam Fuchs
-
Patent number: 5851983Abstract: The present invention provides an elastase inhibitory polypeptide comprising a C-terminal half of a human secretory leukocyte protease inhibitor (SLPI) and having an elastase inhibitory activity wherein inhibitory activity of a trypsin-like serine protease does not exceed 1/10 of elastase inhibitory activity, and polypeptides having the above-mentioned biological activity wherein one or more than one amino acid is added, one or more than one amino acid is deleted and/or one or more than one amino acid is replaced. The present invention also provides a process for the production of the above-mentioned protein or other protein via a corresponding fused protein.Type: GrantFiled: October 20, 1992Date of Patent: December 22, 1998Assignee: Teijin LimitedInventors: Takashi Sugiyama, Takashi Kamimura, Kenichi Masuda, Masahiro Okada, Eiko Ohtsuka, Atsushi Imaizumi, Kunihito Watanabe, Tetsuya Suga, Yohichi Matsumoto, Akiko Takeuchi
-
Patent number: 5821075Abstract: The invention relates to the cloning of two novel protein tyrosine phosphatases. Nucleic acid sequences encoding these phosphatases (PTPL1 and GLM-2) as well as anti-sense sequences are also provided. The recombinantly produced PTPL1 and GLM-2 proteins also are provided, as well as antibodies to these proteins. Methods relating to isolating the phosphatases, using the nucleic acid sequences, and using the phosphatases also are provided.Type: GrantFiled: August 9, 1996Date of Patent: October 13, 1998Assignee: The Ludwig Institute for Cancer ResearchInventors: Leonel Jorge Gonez, Jan Saras, Lana Claesson-Welsh, Carl-Henrik Heldin
-
Patent number: 5821067Abstract: The present invention relates to a novel mammalian met one-specific opioid receptor protein and genes that encode a such protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue or the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: August 15, 1997Date of Patent: October 13, 1998Assignee: State of OregonInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 5747660Abstract: A new protein is described, prostaglandin F.sub.2.alpha. receptor regulatory protein (FPRP), which is able to inhibit the binding of prostaglandin F.sub.2.alpha. (PGF.sub.2.alpha.) to its receptor (FP). Included are pharmaceutical compositions of FPRP and FPRP variants for treatment of PGF.sub.2.alpha. -mediated disorders, and assays for detecting FP in a biological sample.Type: GrantFiled: November 6, 1995Date of Patent: May 5, 1998Assignee: The University of ColoradoInventor: David J. Orlicky
-
Patent number: 5747279Abstract: The subject invention provides recombinant nucleic acid molecule which encodes a kappa.sub.3 opioid receptor, and the receptor encoded thereby. The subject invention further provides related anti-sense oligonucleotide molecules. The subject invention further provides a related host vector system, and method for using same. The subject invention further provides polyclonal and monoclonal antibodies capable of specifically binding to kappa.sub.3 opioid receptor, methods for obtaining same, and methods of using same to detect the presence of, and quantitatively determine the amount of, kappa.sub.3 opioid receptor in a sample, image and quantitatively determine the amount of cell membrane-bound kappa.sub.3 opioid receptor present in a subject, determine a subject's potential sensitivity to a kappa.sub.3 opioid receptor-specific agent, determine the affinity of an agent for kappa.sub.3 opioid receptor, and identify agonists and antagonists of kappa.sub.3 opioid receptor.Type: GrantFiled: November 5, 1993Date of Patent: May 5, 1998Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gavril W. Pasternak, Ying-Xian Pan
-
Patent number: 5691188Abstract: A first aspect of the present invention is directed to a transformed yeast cell containing a first heterologous DNA sequence which codes for a G protein-coupled receptor, for example, the somatostatin receptor, and a second heterologous DNA sequence which codes for a G protein .alpha. subunit or portions thereof fused to DNA sequences from the yeast G protein a subunit. A second aspect of the present invention is a transformed yeast cell containing a heterologous DNA sequence which codes for a G protein coupled receptor. A third aspect of the present invention is a method of assaying compounds to determine effects on cell growth.Type: GrantFiled: February 14, 1994Date of Patent: November 25, 1997Assignee: American Cyanamid CompanyInventors: Mark Henry Pausch, Bradley A. Ozenberger, John Richard Hadcock, Laura Alicia Price, Eileen Marie Kajkowski, Donald Richard Kirsch, Deborah Tardy Chaleff